Holen Sie sich die Stockscreener-App
21.60
1.29%
0.28
Schlusskurs vom Vortag:
$21.32
Offen:
$21.15
24-Stunden-Volumen:
323.18K
Relative Volume:
0.34
Marktkapitalisierung:
$657.91M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-168.05M
KGV:
-4.2105
EPS:
-5.13
Netto-Cashflow:
$-146.15M
1W Leistung:
+28.31%
1M Leistung:
+33.30%
6M Leistung:
+53.26%
1J Leistung:
-67.84%
1-Tages-Spanne:
$20.78
$22.00
1-Wochen-Bereich:
$16.93
$22.55
52-Wochen-Spanne:
$9.12
$69.25
Keros Therapeutics Inc Stock (KROS) Company Profile
Firmenname
Keros Therapeutics Inc
Sektor
Branche
Telefon
617-314-6297
Adresse
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Vergleichen Sie KROS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
21.59 | 649.54M | 0 | -168.05M | -146.15M | -5.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.54 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.32 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
417.88 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
892.74 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.73 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-06-10 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-01-21 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-17 | Herabstufung | Wedbush | Outperform → Neutral |
| 2024-12-16 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-12-16 | Bestätigt | Oppenheimer | Outperform |
| 2024-12-13 | Bestätigt | H.C. Wainwright | Buy |
| 2024-12-12 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-12-12 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-12-12 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-11-05 | Eingeleitet | Jefferies | Buy |
| 2024-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-09-23 | Eingeleitet | Guggenheim | Buy |
| 2024-06-25 | Eingeleitet | Oppenheimer | Outperform |
| 2024-02-21 | Eingeleitet | William Blair | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-07-31 | Eingeleitet | Wedbush | Outperform |
| 2023-07-26 | Eingeleitet | BofA Securities | Buy |
| 2023-02-14 | Eingeleitet | Cowen | Outperform |
| 2022-10-18 | Eingeleitet | Truist | Buy |
| 2022-07-26 | Eingeleitet | BTIG Research | Buy |
| 2020-12-08 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-04 | Eingeleitet | Jefferies | Buy |
| 2020-05-04 | Eingeleitet | Piper Sandler | Overweight |
| 2020-05-04 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Keros Therapeutics Inc Aktie (KROS) Neueste Nachrichten
Myelofibrosis Market to Expand Significantly by 2034, States DelveInsight Report | Lynk Pharma, Samus Therapeutics, Taiga Biotech, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Keros Therapeutics - Barchart.com
Would You Still Hold Keros Therapeutics Stock If It Fell 30%? - Trefis
Can Keros Therapeutics Stock Hold Up When Markets Turn? - Trefis
Keros Therapeutics (NASDAQ:KROS) Trading Up 12%Here's Why - MarketBeat
There's No Escaping Keros Therapeutics, Inc.'s (NASDAQ:KROS) Muted Revenues Despite A 30% Share Price Rise - 富途牛牛
How Keros Therapeutics Inc. stock benefits from tech adoptionWeekly Earnings Recap & Risk Adjusted Buy/Sell Alerts - Newser
Franklin Resources Inc. Grows Stake in Keros Therapeutics, Inc. $KROS - Defense World
Will Keros Therapeutics Inc. stock outperform growth indexesBull Run & Fast Momentum Entry Tips - Newser
Top investors say Keros Therapeutics Inc (KROS) ticks everything they need - Setenews
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Understanding the Setup: (KROS) and Scalable Risk - news.stocktradersdaily.com
TD Cowen Downgrades Keros Therapeutics (KROS) - MSN
Keros Therapeutics (KROS) Gets a Hold from Bank of America Securities - The Globe and Mail
Bank of America Increases Keros Therapeutics (NASDAQ:KROS) Price Target to $19.00 - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Price Target Raised to $19.00 at Bank of America - Defense World
B of A Securities Maintains Keros Therapeutics (KROS) Neutral Recommendation - Nasdaq
How Much Upside is Left in Keros Therapeutics (KROS)? Wall Street Analysts Think 34.24% - MSN
KROS or NVZMY: Which Is the Better Value Stock Right Now? - MSN
ExodusPoint Capital Management, LP's Strategic Acquisition of Ke - GuruFocus
Keros Therapeutics Reports Strong Revenue Growth - MSN
Keros Therapeutics Announces Final Results of Tender Offer - The Manila Times
Latham & Watkins Advises on Keros Therapeutics, Inc.’s US$194.4 Million Tender Offer - Latham & Watkins LLP
The Technical Signals Behind (KROS) That Institutions Follow - news.stocktradersdaily.com
Keros Therapeutics announces final results of tender offer - marketscreener.com
[SC TO-I/A] Keros Therapeutics, Inc. Amended Issuer Tender Offer | KROS SEC FilingForm SC TO-I/A - Stock Titan
Keros Therapeutics (NASDAQ:KROS) Shares Gap DownHere's Why - MarketBeat
Is Keros Therapeutics Inc. stock reversal real or fakeWeekly Investment Summary & Risk Adjusted Buy/Sell Alerts - newser.com
Keros Therapeutics reports oversubscribed $194.4 million tender offer By Investing.com - Investing.com Nigeria
Can Keros Therapeutics Inc. stock maintain operating margins2025 Technical Patterns & Fast Entry High Yield Tips - newser.com
Keros to Repurchase 11 Million Shares in Oversubscribed Tender Offer - MarketScreener
Keros Therapeutics Reports Third Quarter 2025 Financial Results - Sahm
Keros Therapeutics reports oversubscribed $194.4 million tender offer - Investing.com
Keros Therapeutics Announces Preliminary Results of Tender Offer - The Manila Times
Wall Street Analysts See a 42.78% Upside in Keros Therapeutics (KROS): Can the Stock Really Move This High? - MSN
Keros Therapeutics, Inc. (NASDAQ:KROS) Held Back By Insufficient Growth Even After Shares Climb 26% - simplywall.st
How to manage a losing position in Keros Therapeutics Inc.Portfolio Value Report & Free Accurate Trade Setup Notifications - newser.com
Keros Therapeutics, Inc.'s Equity Buyback announced on October 20, 2025, has closed with 10,950,165 shares, representing 26.95% for $194.37 million. - marketscreener.com
How to recover losses in Keros Therapeutics Inc. stockJuly 2025 Price Swings & Accurate Trade Setup Notifications - newser.com
Los Angeles Capital Management LLC Purchases New Stake in Keros Therapeutics, Inc. $KROS - MarketBeat
Is Keros Therapeutics Inc. stock attractive for income investors2025 Buyback Activity & Reliable Entry Point Alerts - newser.com
Connor Clark & Lunn Investment Management Ltd. Boosts Stake in Keros Therapeutics, Inc. $KROS - MarketBeat
Will Keros Therapeutics Inc. stock rally after Fed decisionsWeekly Profit Summary & Daily Chart Pattern Signals - newser.com
Can trapped investors hope for a rebound in Keros Therapeutics Inc.2025 Volatility Report & Safe Entry Momentum Tips - newser.com
Keros Therapeutics Stock Plunges 81% in 3 Months: Here's Why - MSN
Will Keros Therapeutics Inc. price bounce be sustainable2025 Winners & Losers & Comprehensive Market Scan Insights - newser.com
Evaluating Keros Therapeutics Inc. with trendline analysisEntry Point & Short-Term Trading Opportunity Alerts - newser.com
Finanzdaten der Keros Therapeutics Inc-Aktie (KROS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):